Considering the impressive synergistic combination of Apabetalone and SGLT2 inhibitors - and DPP4 inhibitors - my hope for RVX 208 is "stopped early for overwhelming efficacy"

https://twitter.com/GideonHealth/status/1244539915452514305/photo/1

and

https://www.prnewswire.co.uk/news-releases/chmp-issues-positive-opinion-to-extend-invokana-r-canagliflozin-indication-to-reflect-improved-renal-outcomes-in-patients-with-diabetic-kidney-disease-and-type-2-diabetes-862713575.html

both drugs are SGLT2i....and I suspect (hope) we can top their results, either alone, or, in a combination cocktail